CRBP — Q2 2026 Financial Report Analysis

Corbus Pharmaceuticals Q2 2026: a $10 million milestone doubles the quarterly loss as two drugs head into bigger trials

Corbus Pharmaceuticals is a clinical-stage drug developer: it has no approved products and no sales, so its quarterly results are really a measure of how fast it spends cash and what that spending buys. In the second quarter of 2026 (April–June) its net loss roughly doubled to $35.0 million from $17.7 million a year earlier. Most of the jump was one payment: a $10.0 million development milestone paid in April to CSPC Megalith, the Chinese company Corbus licenses its lead cancer drug CRB-701 from. The rest came from heavier clinical spending on both of its programs: CRB-701, a targeted cancer drug, and CRB-913, an oral obesity pill whose first sizeable trial finished dosing in the quarter.

At a glance

• $117.9 million in cash, cash equivalents and investments at June 30, down from about $163.3 million at the end of 2025. Management says this funds operations "into 2028", but the 10-Q itself only commits to "at least twelve months" from the August filing date.
• $31.2 million of research and development (R&D) spending, up 105% from a year ago. Without the one-time $10.0 million milestone, R&D would have been about $21.2 million, still up roughly 39%.
• 19.4 million weighted-average shares, up 59% from 12.2 million, mainly because of a November 2025 stock offering. That is why the loss per share rose only 26% (to $1.81) while the total loss rose 98%.

The numbers

Corbus reports no revenue, so the usual revenue and margin lines don't apply. The figures that matter are spending, the loss, and how much cash is left.

For the first six months, the net loss was $58.0 million versus $34.6 million in the first half of 2025, or $3.04 per share versus $2.83.

Where the money went

The 10-Q breaks R&D down by drug, which shows the shift in priorities clearly:

• CRB-701 is an antibody-drug conjugate, or ADC: an antibody that homes in on a protein called Nectin-4 on cancer cells and carries a chemotherapy payload directly to them. Its costs rose by $14.6 million, "primarily as a result of the $10.0 million development milestone payment made to CSPC in Q2 2026," plus more patients in the ongoing Phase 1/2 trial and preparation for TEMPO-1, a registrational study. A registrational study is the trial a company intends to use to ask regulators for approval. The FDA has cleared TEMPO-1 to proceed in about 250 patients with oropharyngeal cancer (a head-and-neck cancer, often driven by HPV) whose disease has progressed after earlier treatment. Corbus said it expected to start enrolling in September 2026.
• CRB-913 blocks the CB1 receptor, part of the body's cannabinoid system, in a different way from GLP-1 drugs like Wegovy. It is designed to stay out of the brain. Its costs rose $4.1 million as the CANYON-1 Phase 1b trial (254 patients enrolled, per the September readout) worked through treatment; the last patient's last visit happened during the quarter.
• CRB-601, an earlier-stage antibody, has been deprioritized and won't enroll more patients, so its spending fell by $3.0 million.

General and administrative costs (the overhead of running the company) rose $1.0 million, which the filing puts down to more staff ($0.4 million), legal costs ($0.3 million) and recruiting ($0.2 million). The new hires include a Chief Medical Officer and a Chief Business Officer. A company usually hires a business-development lead ahead of partnering talks or, eventually, a product launch.

Takeaway: Corbus now has a lot of clinical work on the go: a Phase 3-scale cancer trial starting and an obesity drug heading into Phase 2. That spending will rise, not fall, while the company has about $118 million and no revenue. Excluding the milestone, it used roughly $22–23 million of cash a quarter in the first half. At that pace the money covers about five more quarters, which is shorter than the "into 2028" runway management describes unless spending stays flat while TEMPO-1 enrolls, or more shares are sold. Shareholders should expect further dilution, which is already happening through the at-the-market program.

What the headline numbers hide

• The jump in the loss is mostly one payment, but the spending trend underneath is real. Without the $10.0 million CSPC milestone, the Q2 net loss would have been about $25.0 million, still about 42% above last year's $17.7 million. More milestones may follow: Corbus still owes CSPC up to $120.0 million in further development and regulatory milestones, plus up to $555.0 million in commercial milestones and low-double-digit royalties if CRB-701 is ever sold. The filing doesn't say when the next development milestone falls due.
• Cash burn tracks the reported loss closely. Cash used in operations in the first half was $55.2 million against a $58.0 million net loss. Only $3.3 million of the loss was non-cash, mostly stock-based pay (about $1.8 million in Q2). Unlike some small biotechs, Corbus's accounting loss is close to its real cash outflow.
• Selling investments, not raising money, paid most of the bills. Investments fell from $134.8 million to $94.6 million as bonds matured or were sold to fund operations. The only new money was $9.1 million (net) from selling 894,044 new shares through an "at-the-market" (ATM) program, which lets the company drip shares into the market at the going price. After the quarter ended, it sold another 738,707 shares for $6.7 million, leaving about $52.8 million of capacity under the ATM program. Corbus also has a $300 million shelf registration, effective since March 2026, which lets it sell securities quickly.
• The share count makes the per-share loss look better than the total. Weighted shares rose 59%, mostly from the November 2025 offering of 4.74 million shares at $13.00 plus 1.025 million pre-funded warrants (rights to shares at a near-zero price, already counted in the share total). Spreading a loss twice as large over many more shares gives a per-share figure that rose only 26%.
• The year-ago comparison has a small one-off of its own. First-half 2025 other income included a $1.1 million employee retention credit (a pandemic-era payroll tax refund) that didn't recur. Interest income is also drifting lower as the cash pile shrinks: $1.2 million in Q2 versus $1.3 million a year ago.
• A cost cut further out. In April, Corbus extended its Norwood, Massachusetts headquarters lease to 2032 and cut the space from 62,756 to 36,471 square feet from December 2026, with base rent of about $65,000 a month from March 2027. It's small next to the R&D budget, but it shows management trimming fixed costs.

What happened after the quarter

Two things in later filings matter for anyone reading these numbers:

• CANYON-1 obesity data (September 14, 2026 8-K). CRB-913 hit statistical significance at all three doses. After 12 weeks, patients on the 60 mg dose had lost 5.0% of their body weight against 0.0% on placebo, and the 40 mg and 20 mg doses gave 3.3% and 2.8%. The company says weight loss hadn't levelled off by week 12. Among patients who completed the study on 60 mg, 44.4% lost at least 5%. Psychiatric side effects are the reason earlier CB1 drugs failed, so they are the key safety question here. Corbus reported no serious psychiatric events, no suicidality, and one moderate, transient depressive symptom among 188 treated patients. Nausea (15–26% across doses) and vomiting (2–8%) were lower than published figures for oral GLP-1 drugs. Those comparisons are between separate, longer trials, though, not head to head. For context, 5% in 12 weeks is a solid early result, but it is well below the roughly 15–20% that leading injectable GLP-1 drugs reach over a year or more. The case for CRB-913 rests on tolerability, the oral form, and possibly combining it with GLP-1s, more than on matching them for weight loss. Corbus plans to talk to the FDA and start a Phase 2 study in the first half of 2027. Full data will be presented at ObesityWeek, November 14–17, 2026.
• TEMPO-1: The plan as of August was to begin enrolling in September 2026. Corbus updated its investor presentation on October 15, but we haven't confirmed from a filing that enrollment has started.

Outlook

Management's own milestones from here: TEMPO-1 enrollment under way, CANYON-1 details at ObesityWeek in November, data on CRB-701 combined with Merck's Keytruda in first-line (newly diagnosed) oropharyngeal cancer in the first quarter of 2027, and a CRB-913 Phase 2 start in the first half of 2027.

Our read: the strategy is coherent. One late-stage cancer bet in a narrow patient group with few options, and one obesity program aimed at the gap GLP-1s leave on tolerability. But the money is the binding constraint. Running a 250-patient registrational trial and starting a Phase 2 obesity study in the same year, on about $118 million plus ATM sales, very likely means more equity raises or a partnership in the next 12–18 months. A good CANYON-1 reception at ObesityWeek is the most obvious opening for either. A partner deal for CRB-913 would be the least dilutive way to fund the obesity program, and hiring a Chief Business Officer is consistent with that route, though the company hasn't said it is pursuing one. In the Q3 report, watch quarterly R&D now that TEMPO-1 is enrolling, how many shares were sold through the ATM program, and whether management repeats "into 2028" for the runway.